Indaptus Therapeutics
INDP
24 hedge funds and large institutions have $979K invested in Indaptus Therapeutics in 2020 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 6 closing their positions.
8% less funds holding
Funds holding: 26 → 24 (-2)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
52% less capital invested
Capital invested by funds: $2.03M → $979K (-$1.05M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$71.3K |
| 2 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$26.5K |
| 3 |
UCFA
United Capital Financial Advisors
Irving,
Texas
|
+$8.82K |
| 4 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
+$8.09K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$7.35K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$414K |
| 2 |
Renaissance Technologies
New York
|
-$356K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$80.1K |
| 4 |
Russell Investments Group
London,
United Kingdom
|
-$29K |
| 5 |
Two Sigma Advisers
New York
|
-$25K |
INDP Hedge Fund Activity: Q3 2020 in Review
24 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Indaptus Therapeutics (INDP) for Q3 2020, worth a combined $979K — down 52% from $2.03M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of INDP and 4 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 4 added.
The largest buyer was GSA Capital Partners, opening a new position worth an estimated $71.3K. The largest seller was Adage Capital Partners, exiting entirely with an estimated $414K sold.
- 24 institutional investors held Indaptus Therapeutics (INDP) as of Q3 2020, down from 26 in Q2 2020.
- Funds reported $979K of Indaptus Therapeutics stock for Q3 2020, down 52% quarter-over-quarter.
- 4 funds opened new Indaptus Therapeutics positions in Q3 2020 and 6 closed out, a net change of -2 holders.
- The largest Indaptus Therapeutics buyer in Q3 2020 was GSA Capital Partners, an estimated $71.3K added.
- The largest Indaptus Therapeutics seller in Q3 2020 was Adage Capital Partners, an estimated $414K sold.
Based on aggregated 13F filings for Q3 2020.